Alcon was among the participants in a round representing the first funding to be disclosed by the cellular ophthalmology therapeutics developer.

Aurion Biotech, a US-based developer of ophthalmology-focused regenerative therapies, received $120m in funding from investors including eyecare product manufacturer Alcon yesterday.

The round was led by investment firm Deerfield Management and also featured Petrichor Healthcare Capital Management, Flying L Partners, Visionary Ventures and Falcon Vision, an ophthalmology-focused vehicle formed by investment firm KKR.

Founded in 2021, Aurion is developing a cellular therapy aimed at corneal oedema secondary to endothelial dysfunction, a condition leading to vision loss that can currently only…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn